You are here

ElSohly Laboratories, Incorporated

Company Information
Address
5 Industrial Park Drive
Oxford, MS 38655
United States


http://www.elsohly.com

Information

DUNS: 157239245

# of Employees: 17


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of a Process for GMP Production of Natural THC and CBD

    Amount: $182,361.00

    Development Process for Production of Natural THC and CBD AbstractTetrahydrocannabinolTHCand cannabidiolCBDare two major constituents of the cannabis plant that have pharmacological properties with po ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  2. An Opioid/Cannabinoid Analgesic that Boosts Pain Relief and Blocks Opiate Reward

    Amount: $180,830.00

    Project Summary Abuse of prescription opioids and fatalities related to their misuse have increased sharply in recent yearsmaking the development of pain medications with reduced abuse potential a maj ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Orally Active Formulations of DHA Dimers for the Treatment of Infectious Diseases

    Amount: $205,514.00

    DESCRIPTION (provided by applicant): The natural product artemisinin is a sesquiterpene endoperoxide with known anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant stra ...

    STTRPhase I2013Department of Health and Human Services National Institutes of Health
  4. Development of Tetrahydrocannabinol Prodrugs for Topical Treatment of Glaucoma

    Amount: $167,381.00

    DESCRIPTION (provided by applicant): Currently, FDA approved clinical applications of 9-Tetrahydrocannabinol (THC) include control of nausea and vomiting associated with chemotherapy and for appe ...

    STTRPhase I2011Department of Health and Human Services National Institutes of Health
  5. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    Amount: $739,218.00

    DESCRIPTION (provided by applicant): Poison ivy/oak contact dermatitis is the most prevalent skin allergy in the United States, affecting gt50% of the adult population. The condition is the major cau ...

    STTRPhase II2009Department of Health and Human Services National Institutes of Health
  6. Transmucosal Intra-Oral Drug Delivery System for THC

    Amount: $743,609.00

    DESCRIPTION (provided by applicant): Delta-9-Tetrahydrocannabinol (THC), the active ingredient in the cannabis plant, has a wide range of pharmacological properties of therapeutic value. The drug has ...

    STTRPhase II2008Department of Health and Human Services National Institutes of Health
  7. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    Amount: $100,074.00

    DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy con ...

    STTRPhase I2006Department of Health and Human Services National Institutes of Health
  8. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    Amount: $100,074.00

    DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy con ...

    SBIRPhase I2006Department of Health and Human Services National Institutes of Health
  9. Transmucosal Intra-Oral Drug Delivery System for THC

    Amount: $99,986.00

    DESCRIPTION (provided by applicant): The overall goal of this research project is to develop an effective, hot-melt extruded "Transmucosal Matrix Patch" (TMP) as a delivery system for Delta-9-Tetrahyd ...

    STTRPhase I2003Department of Health and Human Services National Institutes of Health
  10. SYNTHESIS OF CONJUGATED METABOLITES OF BUPRENOPHINE

    Amount: $93,816.00

    The development of maintenance treatment for subjects with addictive behavior is an important public health issue. Buprenorphine, a promising new drug for the treatment of opiates addition, has been w ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government